News Related to Non-Steroidal Anti-Androgen

Related coverage linked through entity extraction aliases.

BioMarin raises 2026 revenue guidance after Amicus acquisition and FDA PALYNZIQ expansion

May 05, 2026

BioMarin reported first-quarter 2026 revenue of $766 million and raised full-year guidance to $3.825 billion-$3.925 billion. The company highlighted FDA approval of PALYNZIQ for adolescents and upcoming Phase 3 readouts for BMN 401 and VOXZOGO.

Chugai Launches ELEVIDYS as Japan's First Gene Therapy for Duchenne Muscular Dystrophy

Feb 28, 2026

Chugai Pharmaceutical launched ELEVIDYS in Japan as the first regenerative medical product for Duchenne muscular dystrophy following its listing on the National Health Insurance reimbursement price list on February 20, 2026.